Development of Integrated Vectors with Strong Constitutive Promoters for High-Yield Antibiotic Production in Mangrove-Derived <i<Streptomyces</i<
It is important to improve the production of bioactive secondary products for drug development. The <i<Escherichia coli—Streptomyces</i< shuttle vector pSET152 and its derived vector pIB139 containing a strong constitutive promoter <i<ermE</i<p* are commonly used as integrative vectors in actinomycetes. Four new integrative vectors carrying the strong constitutive promoter <i<kasO</i<p*, <i<hrdB</i<p, <i<SCO5768</i<p, and SP44, respectively, were constructed and proven to be functional in different mangrove-derived <i<Streptomyces</i< host strains by using kanamycin resistance gene <i<neo</i< as a reporter. Some biosynthetic genes of elaiophylins, azalomycin Fs, and armeniaspirols were selected and inserted into these vectors to overexpress in their producers including <i<Streptomyces</i< sp. 219807, <i<Streptomyces</i< sp. 211726, and <i<S</i<. <i<armeniacus</i< DSM 43125, resulting in an approximately 1.1–1.4-fold enhancement of the antibiotic yields..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Marine Drugs - 22(2024), 2, p 94 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mingxia Zhao [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Armeniaspirol |
|---|
| doi: |
10.3390/md22020094 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ099616823 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ099616823 | ||
| 003 | DE-627 | ||
| 005 | 20240414043507.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240414s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/md22020094 |2 doi | |
| 035 | |a (DE-627)DOAJ099616823 | ||
| 035 | |a (DE-599)DOAJf95eb8a1857b4457ab643026a1186346 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a QH301-705.5 | |
| 100 | 0 | |a Mingxia Zhao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of Integrated Vectors with Strong Constitutive Promoters for High-Yield Antibiotic Production in Mangrove-Derived <i<Streptomyces</i< |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a It is important to improve the production of bioactive secondary products for drug development. The <i<Escherichia coli—Streptomyces</i< shuttle vector pSET152 and its derived vector pIB139 containing a strong constitutive promoter <i<ermE</i<p* are commonly used as integrative vectors in actinomycetes. Four new integrative vectors carrying the strong constitutive promoter <i<kasO</i<p*, <i<hrdB</i<p, <i<SCO5768</i<p, and SP44, respectively, were constructed and proven to be functional in different mangrove-derived <i<Streptomyces</i< host strains by using kanamycin resistance gene <i<neo</i< as a reporter. Some biosynthetic genes of elaiophylins, azalomycin Fs, and armeniaspirols were selected and inserted into these vectors to overexpress in their producers including <i<Streptomyces</i< sp. 219807, <i<Streptomyces</i< sp. 211726, and <i<S</i<. <i<armeniacus</i< DSM 43125, resulting in an approximately 1.1–1.4-fold enhancement of the antibiotic yields. | ||
| 650 | 4 | |a marine <i<Streptomyces</i< | |
| 650 | 4 | |a integrative vector | |
| 650 | 4 | |a constitutive promoter | |
| 650 | 4 | |a elaiophylin | |
| 650 | 4 | |a azalomycin F | |
| 650 | 4 | |a armeniaspirol | |
| 653 | 0 | |a Biology (General) | |
| 700 | 0 | |a Zhiqiang Yang |e verfasserin |4 aut | |
| 700 | 0 | |a Xinyue Li |e verfasserin |4 aut | |
| 700 | 0 | |a Yaqi Liu |e verfasserin |4 aut | |
| 700 | 0 | |a Yingying Zhang |e verfasserin |4 aut | |
| 700 | 0 | |a Mengqian Zhang |e verfasserin |4 aut | |
| 700 | 0 | |a Yangli Li |e verfasserin |4 aut | |
| 700 | 0 | |a Xincheng Wang |e verfasserin |4 aut | |
| 700 | 0 | |a Zixin Deng |e verfasserin |4 aut | |
| 700 | 0 | |a Kui Hong |e verfasserin |4 aut | |
| 700 | 0 | |a Dongqing Zhu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Marine Drugs |d MDPI AG, 2005 |g 22(2024), 2, p 94 |w (DE-627)DOAJ000101966 |x 16603397 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2024 |g number:2, p 94 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/md22020094 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/f95eb8a1857b4457ab643026a1186346 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/1660-3397/22/2/94 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1660-3397 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2024 |e 2, p 94 | ||